Thermo Fisher Stocks Rise 1.0% as Revenue Growth Beats Estimates

Thermo Fisher Scientific reported Q3 2026 revenue of $12 billion, up 9%. Key segments showed mixed performance: Specialty Diagnostics declined 6%, while Pharma services grew significantly but is expected to slow in Q4. CEO Marc Casper highlighted strong biotech and pharma demand, with AI driving customer investment. The company maintained a 4% Q4 organic growth guide and aims for 7% midterm growth.

Thermo Fisher Scientific (TMO) reported Q3 2026 revenue of $12.14B, up 9%, with adjusted EPS at $6.68, up 15%. Adjusted operating margin expanded to 24.5%. The company raised full-year revenue guidance to $47.7B-$48.2B and adjusted EPS to $25.13-$25.43. Segments showed mixed performance, with Life Sciences Solutions and Specialty Diagnostics lagging.

Thermo Fisher Scientific (TMO) reported Q3 earnings of $6.68 per share, beating estimates by $0.28, with revenue up 9% to $12.14B. However, $0.15 of the EPS beat came from one-time tariff refunds. The company raised its 2026 EPS guidance to $25.13-$25.43. Shares were up 1% to $695. According to the company, organic revenue growth was 6%, with strong performance in Laboratory Products and Biopharma Services.

Thermo Fisher (TMO) reported Q3 2026 revenue growth of 9% to $12.14B, adjusted EPS up 15% to $6.68. Adjusted operating income rose 15% to $2.97B. The company highlighted strong performance across pharma, biotech, and diagnostics, driven by new product launches and strategic initiatives. Thermo Fisher also discussed progress in AI integration and capital deployment, including the Clario acquisition and divestiture of the microbiology business.

Thermo Fisher Scientific reported 6% organic revenue growth in Q3 2026, driven by strong performance in Pharma Services and Analytical Instruments. The company raised its full-year organic revenue growth guidance to 4% and expects free cash flow of $7-7.5 billion. Management attributed growth to market recovery and AI-driven productivity gains, with plans to reinvest tariff refunds into AI and Pharma Services.

Thermo Fisher Scientific (TMO) reported Q3 2026 earnings with adjusted EPS of $6.68 (vs $6.40 expected) and revenue of $12.14B (vs $11.95B expected). Organic growth was 6%, leading to raised full-year guidance. The stock initially fell 2.5% premarket but recovered to +1.63% intraday. Management expects normal growth by late 2027 or early 2028.